Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
aforementioned, Aid, alopecia, ATM, Biden, biometric, bladder, bodyweight, borrower, CAA, carryback, cavity, charitable, checkpoint, chemo, chemoprotection, chemoprotective, CMC, COSELA, covenanted, CTCAE, default, depth, derecognition, derecognized, destruction, distancing, extinguishment, fatal, febrile, FFCR, fight, floor, follicle, forgivable, forthcoming, frontline, fundamentally, futility, GDPR, GTHX, hair, hallmark, hedging, immunochemotherapy, incentivizing, JonesTrading, lessen, Lincoln, loan, lodge, LPC, marginal, metro, migrated, mimicking, monthly, myelosuppression, nationwide, NSCLC, offshore, onsite, overturning, Park, Paycheck, pemetrexed, penalty, pillar, Pleasant, plinabulin, poster, PPP, precautionary, preceding, prevailing, prolong, redirect, reevaluate, Regular, remote, repatriated, rescinded, resell, robust, Satter, shield, skin, SMTP, social, supervisory, sweeping, Symposium, taxation, telemedicine, temporarily, Terminology, thereunder, top, topline, tract, traffic, unforgiven, unpleasant, usage, vision, volunteer, whatsoever, whichever, window, worsen
Removed:
abnormal, absence, additive, Afinitor, arrive, assay, Cambridge, Canaccord, capecitabine, Certified, circulating, cleft, Click, correlation, dabrafenib, deactivating, dealing, decoy, deep, demethylating, depreciated, destroy, detach, dexamethasone, discontinued, dissolution, encouraging, enterprise, exceeded, expression, Fenner, field, fourth, Gazyva, Genuity, hematologic, highest, Hoffman, hybrid, ideal, inactivation, incremental, infusion, inherited, input, intention, invade, investigated, invoicing, killing, kinase, La, localized, Lonsurf, Lynch, MAPK, maturing, median, mediated, melanoma, Merrill, metastasized, mTOR, nanomolar, neutrality, noted, nullifying, obinutuzumab, objective, OPM, overexpressing, overexpression, partially, persistence, Pfizer, pharmacodynamic, Pierce, PK, pocket, power, preference, preservation, profiling, prohibited, PWERM, regime, restore, restrain, retained, Rituxan, rituximab, selectivity, shrink, shrinkage, similarity, Smith, split, stay, structural, subjective, suppression, suppressor, survive, Tafinlar, targeting, Task, undruggable, vemurafenib, vendor, vigilance, worse, Xeloda, Zelboraf
Filing tables
Filing exhibits
ALRN similar filings
Filing view
External links
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-249319 and 333-231143), Form S-3 (Nos. 333-226650, 333-244367 and 333-252587) and Form S-8 (Nos. 333-219158, 333-224785, 333-230592 and 333-237480) of Aileron Therapeutics, Inc. of our report dated March 24, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 24, 2021